Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
New England Journal of Medicine Dec 15, 2017
Neelapu SS, et al. - The efficacy of axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T-cell therapy in patients with refractory large B-cell lymphoma was determined. Patients who received CAR T-cell therapy with axi-cel demonstrated high levels of a durable response.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
